

## LETTER TO THE EDITOR

# Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: Are we due for a second wave of COVID-19 in the fall?

A. Goren<sup>1</sup>, C.G. Wambier<sup>2</sup>, J. McCoy<sup>1</sup>, J. Shapiro<sup>3</sup>, S. Vaño-Galván<sup>4</sup>,  
S. Herrera<sup>5</sup> and L.M. Glode<sup>6</sup>

<sup>1</sup>Applied Biology, Inc. Irvine, CA, United States; <sup>2</sup>Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, United States; <sup>3</sup>Ronald O. Perelman Department of Dermatology at the New York University School of Medicine, NY, USA; <sup>4</sup>Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain; <sup>5</sup>Infectious Diseases Unit, Ramón y Cajal Hospital, Madrid, Spain; <sup>6</sup>University of Colorado Cancer Center, Golden, CO., USA

Received June 9, 2020 – Accepted July 3, 2020

To the Editor,

Over the course of late spring Coronavirus Disease 2019 (COVID-19) diagnosis and hospitalizations have declined in the subtropical northern hemisphere, while in the subtropical southern hemisphere, they have increased. An important question for healthcare preparedness and public policy makers is ‘to what extent is COVID-19 seasonal?’ Viral respiratory infections such as influenza follow a seasonal outbreak cycle; however, it is not known whether severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection follows a seasonal pattern.

SARS-CoV-2 infectivity is dependent on proteolysis of its spike protein by the TMPRSS2 enzyme expressed on the surface of type II pneumocytes in human lung tissue (1). In humans, the only known promoter of the TMPRSS2 gene is an androgen response element (2). In our recent publications, we have presented evidence that males with androgen sensitivity are more likely to exhibit severe symptoms following COVID-19 infection (3). It is important to note that androgen sensitivity denotes a genetic predisposition for genes under the control of the androgen receptor (AR) to be susceptible to the

presence of androgens; this is distinct from the level of androgens present. For example, in androgenetic alopecia both the presence of the androgen sensitivity genotype and high levels of testosterone are required to produce the male pattern baldness phenotype.

A genetic predisposition for androgen sensitivity in males leads to androgenetic alopecia (male pattern hair loss) and increased risk of prostate cancer (4, 5). We have recently reported that among hospitalized men with COVID-19, 79% were diagnosed with androgenetic alopecia compared to the expected prevalence of 31-53% in aged matched controls of similar ethnicity (3). Further, Montopoli et al. (6) observed that COVID-19 infection rates were lower in prostate cancer patients receiving androgen deprivation therapy (ADT) *versus* prostate cancer patients not receiving ADTs (OR 4.05; 95% CI 1.55-10.59). Taken together, it appears that SARS-CoV-2 infectivity is likely to be mediated by androgen sensitivity and may respond to ADT. We are currently exploring this in several studies.

SARS-CoV-2 infection is likely to follow a similar chronobiological pattern. Since a strong dependence on androgen sensitivity has been

*Key words: COVID-19; SARS-CoV-2; androgen receptor; androgenetic alopecia; daylight; sunlight*

Corresponding Author:

Carlos Gustavo Wambier, MD, PhD  
Department of Dermatology,  
Rhode Island Hospital,  
593 Eddy Street, APC building, 10<sup>th</sup> Floor,  
Providence, RI, USA. 02903  
e-mail: carlos\_wambier@brown.edu

0393-974X (2020)

Copyright © by BIOLIFE, s.a.s.

This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder.

Unauthorized reproduction may result in financial and other penalties  
**DISCLOSURE: ALL AUTHORS REPORT NO CONFLICTS OF  
INTEREST RELEVANT TO THIS ARTICLE.**

implied by the epidemiology of severe COVID-19 infections, we hypothesized that seasonal expression of proteins that affect androgen receptor function may provide an explanation. One such gene is the period circadian protein homolog 1 (Per1). Per1 is primarily expressed in the suprachiasmatic nucleus (SCN) located in the hypothalamus; the SCN acts as the primary circadian clock and produces signals that keep the body on an approximate 24-h schedule (7). Environmental cues, most importantly light, are required to reset the circadian clock; the SCN is synchronized via specialized photosensitive ganglion cells (photosensitive retinal ganglion cells) present in the retina. Per1 expression follows the circadian cycle of the SCN and is mediated by the seasonality of available light. Sumova et al. (8) demonstrated that rats exposed to a longer photoperiod (16 hours light and 8 hours darkness) exhibited at least 4 additional hours of Per1 expression compared to rats exposed to a shorter photoperiod (8 hours light and 16 hours darkness).

Per1 expression has been demonstrated to mediate androgen receptor function. Cao et al. demonstrated that Per1 inhibited transactivation of the AR. Moreover, they showed that overexpression of Per1 diminished the expression of androgen-sensitive genes following the addition of dihydrotestosterone. Finally, the overexpression of Per1 in prostate cancer cells inhibited their growth and led to apoptosis (7).

Other seasonally expressed genes have also been demonstrated to affect the androgen receptor. Dopico et al. (9) demonstrated large seasonal immune and endocrine variation in the expression of clock genes; they reported increased expression of estradiol receptor genes during summer and increased expression of IL-6 receptor genes in the winter. IL-6 regulates androgen receptor activity by causing ligand and synergistic activation of the AR. Such effect is down-regulated by nonsteroidal antagonists of the AR (10). Additionally, prostate specific antigen (PSA) levels have been shown to vary seasonally (11).

Taken together, longer day light associated with spring and summer months are likely to reduce androgen sensitivity. Reduced androgen sensitivity would lead to lower expression of TMPRSS2 and subsequently may reduce SARS-CoV-2 infectivity.

Conversely, the lower available daylight associated with fall and winter months is likely to increase SARS-CoV-2 infectivity. While it is postulated that influenza's seasonal infectiveness rate is mediated by changes in immune response, it is important to note that influenza entry into lung cells is also dependent on the TMPRSS2 enzyme (12) and, as such, may be influenced by variation in the length of the daylight. It would be interesting to study the degree of variation in influenza's seasonal infectivity as a function of geographic latitude, i.e., would smaller annual variations in length of day (e.g., at the equator) lead to a broader distribution of annual influenza infection rates. In conclusion, because both SARS-CoV-2 and influenza are dependent on TMPRSS2 for infectivity, it is likely that SARS-CoV-2 will have a similar seasonal cycle; thus, the fall and winter are likely to see an increase in COVID-19 cases.

## REFERENCES

1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; 181(2):271-80. doi:10.1016/j.cell.2020.02.052
2. Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov* 2014; 4(11):1310-25. doi:10.1158/2159-8290.CD-13-1010
3. Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity [published online ahead of print, 2020 Apr 16]. *J Cosmet Dermatol* 2020. doi:10.1111/jocd.13443
4. Kim HS, Moreira DM, Jayachandran J, et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. *Prostate Cancer Prostatic Dis* 2011; 14(3):262-65. doi:10.1038/pcan.2011.18
5. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. *J Invest Dermatol* 2001; 116(3):452-

55. doi:10.1046/j.1523-1747.2001.01261.x
6. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) [published online ahead of print, 2020 May 4]. *Ann Oncol* 2020; S0923-7534(20)39797-0. doi:10.1016/j.annonc.2020.04.479
7. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP. A role for the clock gene *per1* in prostate cancer. *Cancer Res* 2009; 69(19):7619-25. doi:10.1158/0008-5472.CAN-08-4199
8. Sumová A, Sládek M, Jác M, Illnerová H. The circadian rhythm of *Per1* gene product in the rat suprachiasmatic nucleus and its modulation by seasonal changes in daylength. *Brain Res* 2002; 947(2):260-70. doi:10.1016/s0006-8993(02)02933-5
9. Dopico, X., Evangelou, M., Ferreira, R. et al. Widespread seasonal gene expression reveals annual differences in human immunity and physiology. *Nat Commun* 2015; 6,7000. <https://doi.org/10.1038/ncomms8000>
10. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. *Mol Cell Endocrinol* 2002; 197(1-2):231-38. doi:10.1016/s0303-7207(02)00263-0
11. Salama G, Noirot O, Bataille V, Malavaud S, Rebillard X, Villers A, Malavaud B. Seasonality of serum prostate-specific antigen levels: a population-based study. *Eur Urol* 2007; 52(3):708-14. doi:10.1016/j.eururo.2006.11.042
12. Sakai K, Ami Y, Tahara M, et al. The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses. *J Virol* 2014; 88(10):5608-16. doi:10.1128/JVI.03677-13